Immuno-Grade 5-HT6 Receptor Antibodies

The 5-HT6 receptor is a G protein-coupled receptor (GPCR) that mediates the effects of serotonin (5-hydroxytryptamine, 5-HT) and is primarily involved in cognitive function, learning, memory, and mood regulation. Expression of the 5-HT6 receptor is largely restricted to the central nervous system, with high levels in the striatum, cortex, hippocampus, and nucleus accumbens, where it is regulated by neuronal activity and developmental processes. Upon activation, the receptor primarily couples to Gs proteins, stimulating adenylyl cyclase activity and increasing intracellular cyclic AMP (cAMP) levels, thereby influencing multiple downstream signaling pathways. The 5-HT6 receptor also modulates the release of neurotransmitters such as acetylcholine, glutamate, dopamine, and GABA, contributing to its role in higher brain functions. Receptor activity is regulated through ligand-induced desensitization, phosphorylation, and internalization after prolonged stimulation. Dysregulation of 5-HT6 signaling has been associated with Alzheimer's disease, schizophrenia, depression, and other neuropsychiatric disorders. Although numerous selective 5-HT6 receptor antagonists and agonists have entered clinical development for cognitive impairment and dementia, no highly selective 5-HT6-targeted drug has yet received regulatory approval for clinical use. The 5-HT6 receptor is a GPCR that couples via Gs to increase cAMP production. The receptor is structurally differentiated from the other 5-HT receptors with less than 34% amino acid sequence identity. Various selective 5-HT6 receptor antagonists have been described (e.g. SB742457) and selective agonists are becoming available (e.g. EMD386088). A number of non-selective drugs used to treat schizophrenia (e.g. olanzepine, clozapine, zotepine), also display high affinity for the 5-HT6 receptor, although the consequences of this are not clear. Selective 5-HT6 antagonists induce precognitive effects in animal models. 5-HT6 receptors are regulated by phosphorylation of carboxyl-terminal serine350/serine352 (pS350/pS352-5-HT6) and threonine355/serine356 (pT355/pS356-5-HT6) residues. This nomenclature refers to the human 5-HT6. For more information on 5-HT6 pharmacology please refer to the IUPHAR database. For further reading refer to:

Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994 Jun;46(2):157-203. PMID: 7938165.

Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, Claeysen S, Cunningham KA, Fone KC, Gershon M, Di Giovanni G, Goodfellow NM, Halberstadt AL, Hartley RM, Hassaine G, Herrick-Davis K, Hovius R, Lacivita E, Lambe EK, Leopoldo M, Levy FO, Lummis SCR, Marin P, Maroteaux L, McCreary AC, Nelson DL, Neumaier JF, Newman-Tancredi A, Nury H, Roberts A, Roth BL, Roumier A, Sanger GJ, Teitler M, Sharp T, Villalón CM, Vogel H, Watts SW, Hoyer D. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacol Rev. 2021 Jan;73(1):310-520. doi: 10.1124/pr.118.015552. PMID: 33370241; PMCID: PMC7770494.

Bockaert J, Claeysen S, Compan V, Dumuis A. 5-HT(4) receptors, a place in the sun: act two. Curr Opin Pharmacol. 2011 Feb;11(1):87-93. doi: 10.1016/j.coph.2011.01.012. Epub 2011 Feb 20. PMID: 21342787.